With Intercept (ICPT) preparing to release Phase 3 results from its REGENERATE study in Non-Alcoholic Steatohepatitis (NASH) patients, Gilead (GILD) announced yesterday that its top late-stage NASH drug …
It’s a very rewarding trading day for investors in MacroGenics (MGNX) with shares up over 120%, making the stock Wall Street’s bull of …
Shares of Trevena (TRVN) came back to life. The struggling biotech stock took a rare leap upward last week, as well as today, as resolution …
Congrats. Evolus (EOLS) is the first company to win FDA approval for a neurotoxin that is considered biosimilar to branded Botox for the …
The turnaround at Teva Pharmaceutical Industries (TEVA) remains on schedule. Investors appear satisfied that CEO Kare Schultz is making enough progress in battling …
Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.
Investors love healthcare stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Shares of …
Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …
Send ResMed (RMD) shares tanked nearly 18% today, leaving investors at odds over when it will hit a bottom. What’s causing investors to hit …
TherapeuticsMD (TXMD) investors are keeping an eye on the pace of commercialization efforts for Imvexxy, Annovera, and Bijuva. That will prove critical for …
